#pharma-competition

[ follow ]
#novo-nordisk #glp-1-therapies #drug-innovation #pfizermetsera-acquisition #obesityweight-loss-drugs
Healthcare
fromFortune
2 days ago

Novo Nordisk wants to keep its crown leading the weight loss drugs pack-despite outlook downgrades and lawsuits, its CFO has a plan | Fortune

Novo Nordisk faces declining sales and stock after GLP-1 competition; success depends on launching new products like Wegovy pill, CagriSema, and amycretin.
Medicine
fromFast Company
1 month ago

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is acquiring Metsera and its four obesity and cardiometabolic drug candidates for up to $7.3 billion to enter the weight-loss market.
[ Load more ]